Coverage
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets as it navigates a period of strategic and leadership transition.
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets, and forecast a similar performance for the year ahead as it implements a new strategy.
Coloplast interim Chief Executive Lars Rasmussen will step down from the company's board of directors, the latest leadership change at the Danish medical device maker as it implements a new strategy.
Danish medical device maker Coloplast on Tuesday unveiled a new five-year strategy that tempers its long-term growth forecast.
Danish medical device maker Coloplast on Tuesday tempered its long-term growth forecast as it unveiled a new five-year strategy, dubbed "Impact4."
Danish medical device maker Coloplast announced a significant overhaul of its executive team and corporate structure on Tuesday, moves it said are designed to support a new long-term strategy.
Filings
| Filing | Date |
|---|---|
| Insider's tradings | 29 May 2018 |
| Share buy-back week 21/2018 | 28 May 2018 |
| Insider's tradings | 23 May 2018 |
| Share buy-back week 20/2018 | 22 May 2018 |
| Share buy-back week 19/2018 | 14 May 2018 |
| Insider's tradings | 9 May 2018 |
| Share buy-back week 18/2018 | 7 May 2018 |
| Coloplast delivers 8% organic revenue growth and upgrades full-year growth expectations | 3 May 2018 |
| Announcement no. 4/2018 - Interim Financial Report, H1 2017/18 | 3 May 2018 |
| Share buy-back week 17/2018 | 30 Apr 2018 |
| Share buy-back week 16/2018 | 23 Apr 2018 |
| Share buy-back week 15/2018 | 16 Apr 2018 |